Streetbeat News

Analyst Ratings

TGT

Jefferies analyst Corey Tarlowe maintains a Buy rating on Target (NYSE:TGT) and raises the price target from $170 to $195.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:42 pm

APGE

Jefferies analyst Akash Tewari has maintained a Buy rating on Apogee Therapeutics (NASDAQ:APGE) and increased the price target from $37 to $75.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:38 pm

ROST

Jefferies analyst Corey Tarlowe maintains a Hold rating on Ross Stores (NASDAQ:ROST) and raises the price target from $135 to $147.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:36 pm

RGNX

Leerink Partners analyst Mani Foroohar upgrades Regenxbio (NASDAQ:RGNX) from Market Perform to Outperform, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:33 pm

NTRA

Piper Sandler analyst David Westenberg maintains an Overweight rating on Natera (NASDAQ:NTRA) and raises the price target from $70 to $110.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:32 pm

FERG

Jefferies analyst Philip Ng maintains a Buy rating on Ferguson (NYSE:FERG) and raises the price target from $222 to $244.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:32 pm

FLGT

Piper Sandler analyst David Westenberg maintains a Neutral rating on Fulgent Genetics (FLGT) and lowers the price target from $28 to $25.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:31 pm

CTKB

Piper Sandler analyst David Westenberg maintains an Overweight rating on Cytek Biosciences (CTKB) but lowers the price target from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:30 pm

DYN

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) and increased the price target from $27 to $29.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:28 pm

JWN

Piper Sandler analyst Edward Yruma maintains a Neutral rating on Nordstrom (JWN) and raises the price target from $17 to $20.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 2:26 pm